Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment

Angel A. Justiz-Vaillant,Darren Gopaul,Sachin Soodeen,Rodolfo Arozarena-Fundora,Odette Arozarena Barbosa,Chandrashehkar Unakal,Reinand Thompson,Bijay Pandit,Srikanth Umakanthan,Patrick E. Akpaka

DOI: https://doi.org/10.3390/molecules29040747

IF: 4.6

2024-02-06

Molecules

Abstract:Systemic lupus erythematosus (SLE) is an idiopathic chronic autoimmune disease that can affect any organ in the body, including the neurological system. Multiple factors, such as environmental (infections), genetic (many HLA alleles including DR2 and DR3, and genes including C4), and immunological influences on self-antigens, such as nuclear antigens, lead to the formation of multiple autoantibodies that cause deleterious damage to bodily tissues and organs. The production of autoantibodies, such as anti-dsDNA, anti-SS(A), anti-SS(B), anti-Smith, and anti-neuronal DNA are characteristic features of this disease. This autoimmune disease results from a failure of the mechanisms responsible for maintaining self-tolerance in T cells, B cells, or both. Immune complexes, circulating antibodies, cytokines, and autoreactive T lymphocytes are responsible for tissue injury in this autoimmune disease. The diagnosis of SLE is a rheumatological challenge despite the availability of clinical criteria. NPSLE was previously referred to as lupus cerebritis or lupus sclerosis. However, these terms are no longer recommended because there is no definitive pathological cause for the neuropsychiatric manifestations of SLE. Currently, the treatment options are primarily based on symptomatic presentations. These include the use of antipsychotics, antidepressants, and anxiolytic medications for the treatment of psychiatric and mood disorders. Antiepileptic drugs to treat seizures, and immunosuppressants (e.g., corticosteroids, azathioprine, and mycophenolate mofetil), are directed against inflammatory responses along with non-pharmacological interventions.

chemistry, multidisciplinary,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the immunopathogenesis, clinical features and treatment regimens of neuropsychiatric system involvement (NPSLE) in systemic lupus erythematosus (SLE). Specifically, the paper explores the following aspects:

1. **Molecular Involvement**: The paper describes in detail the molecules that play a key role in NPSLE, including autoantibodies, cytokines and other immune mediators. How these molecules affect the normal function of the nervous system and lead to the occurrence and development of neuropsychiatric symptoms.

2. **Clinical Manifestations**: The paper summarizes the clinical features of NPSLE, including cognitive impairment, organic brain syndrome, delirium, epileptic seizures, headache and psychosis. These symptoms may affect the central nervous system (CNS) and the peripheral nervous system (PNS) and can be manifested as a variety of different symptoms.

3. **Diagnostic Challenges**: Although clinical criteria are available, the diagnosis of SLE remains a challenge in rheumatology. The diagnosis of NPSLE is particularly complex because its neuropsychiatric symptoms may be confused with other diseases or drug side effects.

4. **Treatment Strategies**: Current treatment regimens are mainly based on symptom manifestations, including the use of antipsychotics, antidepressants and anxiolytics to treat psychological and emotional disorders, the use of antiepileptic drugs to control epileptic seizures, and the use of immunosuppressants (such as corticosteroids, azathioprine and mycophenolate mofetil) to combat the inflammatory response. In addition, non - drug intervention measures are also included.

5. **Immunopathogenesis**: The paper delves into the immunopathogenesis of NPSLE, including genetic factors (such as TREX1 gene and HLA - DRB1*04), cytokines (such as IFN - γ, IL - 17F, IL - 21, IL - 18, GM - CSF and VEGF), immune cells (such as autoantibodies produced by B cells and pro - inflammatory cytokines produced by T cells) and environmental factors (such as infection, stress, smoking and ultraviolet exposure).

6. **Pathophysiology**: The paper discusses the pathophysiology of NPSLE, including how autoantibodies cross the blood - brain barrier (BBB) and bind to brain tissue, leading to inflammation and damage; how cytokines mediate inflammation and immune responses, thereby triggering neuropsychiatric symptoms; and how the destruction of the BBB and vascular lesions promote the development of NPSLE.

Through the exploration of these aspects, the paper aims to provide a more comprehensive understanding of the diagnosis, treatment and management of NPSLE and lay the foundation for further research.